Erratum: Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large scale study (Journal of Autism and Developmental Disorders DOI:10.1007/s10803-012-1617-6);Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large scale study

Journal of Autism and Developmental Disorders

Volumn 43, Issue 3, 2013, Pages 719-731

  Tsiouris, John A ^a   Kim, Soh Yule ^a   Brown, W Ted ^a   Pettinger, Jill ^b   Cohen, Ira L ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b OPWDD Statewide Services   (United States)

Author keywords

Aggression; Challenging behavior; Diagnosis; Intellectual disability; Psychotropics; Survey

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; AGGRESSION; ARTICLE; AUTISM; BEHAVIOR DISORDER; DRUG USE; EVIDENCE BASED PRACTICE; FEMALE; GENERAL PRACTITIONER; HUMAN; INTELLECTUAL IMPAIRMENT; LARGE SCALE PRODUCTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEIZURE;

EID: 84873909396     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-012-1634-5     Document Type: Erratum

References (65)

1. Alexander, G. C.; Gallagher, S. A.; Mascola, A.; Moloney, R. M.; Stafford, R. S. (2011). Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiology and Drug Safety, 20, 177-184.
2. Aman, M.; Buitelaar, J.; Smedt, G. D.; Wapenaar, R.; Binder, C. (2005). Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: Pooled analysis of risperidone effects in children with subaverage IQ. Journal of Child and Adolescent Psychopharmacology, 15, 220-232.
3. Aman, M. G.; Burrow, W. H.; Wolford, P. L. (1995). The Aberrant Behavior Checklist-Community: Factor validity and effect of subject variables for adults in group homes. American Journal of Mental Retardation, 100, 283-292.
4. Aman, M. G.; De, S. G.; Derivan, A.; Lyons, B.; Findling, R. L. (2002). Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry, 159, 1337-1346.
5. Aman, M. G.; Field, C. J.; Bridgman, G. D. (1985). City-wide survey of drug patterns among non-institutionalized mentally retarded persons. Applied Research in Mental Retardation, 6, 159-171.
6. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders-IV. Washington, DC: American Psychiatric Association.
7. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders fourth edition text revision. Washington DC: American Psychiatric Association.
8. Branford, D. (1994). A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. Journal of Intellectual Disabilities Research, 38(Pt 6), 577-586.
9. Clarke, D. J.; Gomez, G. A. (1999). Utility of modified DCR-10 criteria in the diagnosis of depression associated with intellectual disability. Journal of Intellectual Disabilities Research, 43(Pt 5), 413-420.
10. Clarke, D. J.; Kelley, S.; Thinn, K.; Corbett, J. A. (1990). Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. Journal of Mental Deficiency Research, 34(Pt 5), 385-395.
11. Cohen, I. L.; Tsiouris, J. A.; Flory, M. J.; Kim, S.-Y.; Freedland, R.; Heaney, G.; et al. (2010). A large scale study of the psychometric characteristics of the IBR Modified Overt Aggression Scale: Findings and evidence for increased self-destructive behaviors in adult females with Autism Spectrum Disorder. Journal of Autism and Developmental Disorder, 40, 599-609.
12. Cooper, S. A.; Melville, C. A.; Einfeld, S. L. (2003). Psychiatric diagnosis, intellectual disabilities and diagnostic criteria for psychiatric disorders for use with adults with learning disabilities/mental retardation (DC-LD). Journal of Intellectual Disabilities Research, 47(Suppl 1), 3-15.
13. Cooper, S. A.; Smiley, E.; Allan, L. M.; Jackson, A.; Finlayson, J.; Mantry, D.; et al. (2009). Adults with intellectual disabilities: Prevalence, incidence and remission of self-injurious behaviour, and related factors. Journal of Intellectual Disabilities Research, 53, 200-216.
14. Cooper, S. A.; Smiley, E.; Morrison, J.; Williamson, A.; Allan, L. (2007). Mental ill-health in adults with intellectual disabilities: Prevalence and associated factors. British Journal of Psychiatry, 190, 27-35.
15. Crocker, A. G.; Mercier, C.; Allaire, J. F.; Roy, M. E. (2007). Profiles and correlates of aggressive behaviour among adults with intellectual disabilities. Journal of Intellectual Disabilities Research, 51, 786-801.
16. Crocker, A. G.; Mercier, C.; Lachapelle, Y.; Brunet, A.; Morin, D.; Roy, M. E. (2006). Prevalence and types of aggressive behaviour among adults with intellectual disabilities. Journal of Intellectual Disability Research, 50, 652-661.
17. de Kuijper, G.; Hoekstra, P.; Visser, F.; Scholte, F. A.; Penning, C.; Evenhuis, H. (2010). Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: Prevalence and reasons for prescription. Journal of Intellectual Disabilities Research, 54, 659-667.
18. Deb, S.; Fraser, W. (1994). The use of psychotropic medication in people with learning disability: Towards rational prescribing. Human Psychopharmacology, 9, 259-272.
19. Deb, S.; Kwok, H.; Bertelli, M.; Salvador-Carulla, L.; Bradley, E.; Torr, J.; et al. (2009). International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry, 8, 181-186.
20. Deb, S.; Sohanpal, S. K.; Soni, R.; Lenotre, L.; Unwin, G. (2007). The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. Journal of Intellectual Disabilities Research, 51, 766-777.
21. Duggan, L.; Brylewski, J. (1999). Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: A systematic review. Journal of Intellectual Disabilities Research, 43(Pt 2), 94-104.
22. Fleming, I.; Caine, A.; Ahmed, S.; Smith, S. (1996). Aspects of the use of psychoactive medication among people with intellectual disabilities who have been resettled from long-stay hospitals into dispersed housing. Journal of Applied Research in Intellectual Disabilities, 9, 194-205.
23. Fletcher, R.; Loschen, E.; Stavrakaki, C.; First, M. (2007). Diagnostic Manual-Intellectual Disability (DM-ID): A textbook of diagnosis of mental disorders in persons with intellectual disability. Kingston, NY: NADD Press.
24. Frighi, V.; Stephenson, M. T.; Morovat, A.; Jolley, I. E.; Trivella, M.; Dudley, C. A.; et al. (2011). Safety of antipsychotics in people with intellectual disability. British Journal of Psychiatry, 199, 289-295.
25. Gadow, K. D.; Kalachnik, J. (1981). Prevalence and pattern of drug treatment for behavior and seizure disorders of TMR students. American Journal of Mental Deficiency, 85, 588-595.
26. Greendyke, R. M.; Kanter, D. R. (1986). Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: A double-blind study. Journal of Clinical Psychiatry, 47, 423-426.
27. Greendyke, R. M.; Kanter, D. R.; Schuster, D. B.; Verstreate, S.; Wootton, J. (1986). Propranolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study. Journal of Nervous and Mental Deficiencies, 174, 290-294.
28. Harper, D. C.; Wadsworth, J. S. (1993). Behavioral problems and medication utilization. Mental Retardation, 31, 97-103.
29. Hill, B. K.; Balow, E. A.; Bruininks, R. H. (1985). A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacology Bulletin, 21, 279-284.
30. Holden, B.; Gitlesen, J. P. (2004). Psychotropic medication in adults with mental retardation: Prevalence, and prescription practices. Research in Developmental Disabilities, 25, 509-521.
31. Hurley, A. D. (2008). Depression in adults with intellectual disability: Symptoms and challenging behaviour. Journal of Intellectual Disabilities Research, 52, 905-916.
32. Intagliata, J.; Rinck, C. (1985). Psychoactive drug use in public and community residential facilities for mentally retarded persons. Psychopharmacology Bulletin, 21, 268-278.
33. Jones, S.; Cooper, S. A.; Smiley, E.; Allan, L.; Williamson, A.; Morrison, J. (2008). Prevalence of, and factors associated with, problem behaviors in adults with intellectual disabilities. Journal of Nervous and Mental Deficiencies, 196, 678-686.
34. Kiernan, C.; Reeves, D.; Alborz, A. (1995). The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour. Journal of Intellectual Disability Research, 39, 263-274.
35. La Malfa, G.; Bertelli, M.; Conte, M. (2001). Fluvoxamine and aggression in mental retardation. Psychiatric Services, 52, 1105.
36. Long, J. S.; Freese, J. (2006). Regression models for categorical dependent variables using stata (2nd ed.). College Station, TX: Stata Press.
37. Mahan, S.; Holloway, J.; Bamburg, J. W.; Hess, J. A.; Fodstad, J. C.; Matson, J. L. (2010). An Examination of psychotropic medication side effects: Does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID? Research in Developmental Disabilities, 31, 1561-1569.
38. Martin, J. E.; Agran, M. (1985). Psychotropic and anticonvulsant drug use by mentally retarded adults across community residential and vocational placements. Applied Research in Mental Retardation, 6, 33-49.
39. Matson, J. L.; Mahan, S. (2010). Antipsychotic drug side effects for persons with intellectual disability. Research in Developmental Disabilities, 31, 1570-1576.
40. Matson, J. L.; Wilkins, J. (2008). Antipsychotic drugs for aggression in intellectual disability. Lancet, 371, 9-10.
41. Molyneux, P.; Emerson, E.; Caine, A. (1999). Prescription of psychotropic medication to people with intellectual disabilities in primary health-care settings. Journal of Applied Research in Intellectual Disabilities, 12, 46-57.
42. Moss, S. C.; Prosser, H.; Costello, H.; Simpson, N.; Patel, P. (1996). PAS-ADD checklist. Manchester: Hester Adrian Research Centre, University of Manchester.
43. Myrbakk, E.; von Tetzchner, T. S. (2008). Psychiatric disorders and behavior problems in people with intellectual disability. Research in Developmental Disabilities, 29, 316-332.
44. Neece, C. L.; Baker, B. L.; Blacher, J.; Crnic, K. A. (2011). Attention-deficit/hyperactivity disorder among children with and without intellectual disability: An examination across time. Journal of Intellectual Disabilities Research, 55, 623-635.
45. Oliver-Africano, P.; Murphy, D.; Tyrer, P. (2009). Aggressive behaviour in adults with intellectual disability: Defining the role of drug treatment. CNS Drugs, 23, 903-913.
46. Paton, C.; Flynn, A.; Shingleton-Smith, A.; McIntyre, S.; Bhaumik, S.; Rasmussen, J.; et al. (2011). Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. Journal of Intellectual Disabilities Research, 55, 665-674.
47. R Development Core Team. (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org/.
48. Robertson, J.; Emerson, E.; Gregory, N.; Hatton, C.; Kessissoglou, S.; Hallam, A. (2000). Receipt of psychotropic medication by people with intellectual disability in residential settings. Journal of Intellectual Disability Research, 44, 666-676.
49. Romeo, R.; Knapp, M.; Tyrer, P.; Crawford, M.; Oliver-Africano, P. (2009). The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis. Journal of Intellectual Disabilities Research, 53, 633-643.
50. Rosenberg, R. E.; Mandell, D. S.; Farmer, J. E.; Law, J. K.; Marvin, A. R.; Law, P. A. (2010). Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. Journal of Autism and Developmental Disorder, 40, 342-351.
51. Ruedrich, S. L.; Grush, L.; Wilson, J. (1990). Beta adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. American Journal of Mental Retardation, 95, 110-119.
52. Scheifes, A.; Stolker, J. J.; Egberts, A. C.; Nijman, H. L.; Heerdink, E. R. (2011). Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems. Journal of Intellectual Disabilities Research, 55, 650-664.
53. Shedlack, K. J.; Hennen, J.; Magee, C.; Cheron, D. M. (2005). Assessing the utility of atypical antipsychotic medication in adults with mild mental retardation and comorbid psychiatric disorders. Journal of Clinical Psychiatry, 66, 52-62.
54. Silva, D. A. (1979). The use of medication in a residential institution for mentally retarded persons. Mental Retardation, 17, 285-288.
55. Singh, A. N.; Matson, J. L.; Cooper, C. L.; Dixon, D.; Sturmey, P. (2005). The use of risperidone among individuals with mental retardation: Clinically supported or not? Research in Developmental Disabilities, 26, 203-218.
56. Szalavitz, M. (2011, May 26). Drugging the vulnerable: Atypical antipsychotics in children and the elderly. Time:Heathland. Retrieved July 18, 2012 from http://healthland.time.com.
57. Tsiouris, J. A. (2010). Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: Treatment or mistreatment? Journal of Intellectual Disabilities Research, 54, 1-16.
58. Tsiouris, J.; Cohen, I. L.; Patti, P. J.; Korosh, W. M. (2003). Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior. Journal of Clinical Psychiatry, 62, 1081-1090.
59. Tsiouris, J. A.; Kim, S. Y.; Brown, W. T.; Cohen, I. L. (2011). Association of aggressive behaviours with psychiatric disorders, age, sex and degree of intellectual disability: A large-scale survey. Journal of Intellectual Disabilities Research, 55, 636-649.
60. Tyrer, P.; Oliver-Africano, P.; Ahmed, Z.; Bouras, N.; Cooray, S.; Deb, S.; et al. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomised controlledtrial. Lancet, 371, 63.
61. Wilson, D. (2009). Poor children likelier to get antipsychotics. New York: New York Times.
62. World Health Organization. (1978). Mental disorders: Glossary and guide to their classification in accordance with the ninth revision of the international classification of diseases. Geneva: World Health Organization.
63. Wright, D. B.; Strubler, K. A.; Vallano, J. P. (2011). Statistical techniques for juror and jury research. Legal and Criminological Psychology, 16, 90-125.
64. Yudofsky, S. C.; Silver, J. M.; Jackson, W.; Endicott, J.; Williams, D. (1986). The Overt Aggression Scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry, 143, 35-39.
65. Zeiles, A. (2008). Regression models for count data in R. Journal of Statistical Software, 27, 8.